Contribution of TNFα, IL-1β and CINC-1 for articular incapacitation, edema and cell migration in a model of LPS-induced reactive arthritis

Cytokine

Volumn 36, Issue 1-2, 2006, Pages 83-89

  Bressan, Elisângela ^a   De Queiroz Cunha, Fernando ^b   Tonussi, Carlos Rogério ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antibody; Arthritis; Chemokine; Cytokine; Inflammation; LPS; Pain

Indexed keywords

ANTISERUM; BACTERIUM LIPOPOLYSACCHARIDE; CARRAGEENAN; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 1; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 1 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; ALPHA CHEMOKINE; ANTIBODY; CXCL1 PROTEIN, RAT; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHROPATHY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DISEASE MODEL; EDEMA; EVALUATION; KNEE FUNCTION; MALE; MONONUCLEAR CELL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; REACTIVE ARTHRITIS; SYNOVIAL FLUID; WALKING; WISTAR RAT; ANIMAL; CELL MOTION; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; LEUKOCYTE COUNT; METABOLISM; PATHOLOGY;

ANIMALIA; ESCHERICHIA COLI; RATTUS;

ANIMALS; ANTIBODIES; ARTHRITIS, REACTIVE; CELL MOVEMENT; CHEMOKINES, CXC; DISEASE MODELS, ANIMAL; EDEMA; INTERLEUKIN-1BETA; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, WISTAR; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845981116     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.11.007     Document Type: Article

References (48)

1. Steiner G., Tohidast-Akrad M., Witzmann G., Vesely M., Studnicka-Benke A., Gal A., Kunaver M., Zenz P., and Smolen J.S. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology 38 3 (1999) 202-213
2. Fontana A., Hengartner H., Weber E., Fehr K., Grob P.J., and Cohen G. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 2 2 (1982) 49-53
3. Braddock M., and Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 3 4 (2004) 330-339
4. Di Giovine F.S., Nuki G., and Duff G.W. Tumour necrosis factor in synovial exudates. Ann Rheum Dis 47 9 (1988) 768-772
5. Feldmann M., Brennan F.M., Williams R.O., Woody J.N., and Maini R.N. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 18 1 (2004) 59-80
6. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
7. Kuiper S., Joosten L.A., Bendele A.M., Edwards III C.K., Arntz O.J., Helsen M.M., Van de Loo F.A., and Van den Berg W.B. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 10 9 (1998) 690-702
8. van den Berg W.B. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 3 1 (2000) 18-26
9. Vilcek J., and Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 25 4 (2004) 201-209
10. Butrimiene I., Jarmalaite S., Ranceva J., Venalis A., Jasiuleviciute L., and Zvirbliene A. Different cytokine profiles in patients with chronic and acute reactive arthritis. Rheumatology 43 10 (2004) 1300-1304
11. Partsch G., Steiner G., Leeb B.F., Dunky A., Broll H., and Smolen J.S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24 3 (1997) 518-523
12. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., Eggens U., Distler A., and Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38 4 (1995) 499-505
13. Burgos-Vargas R. Juvenile onset spondyloarthropathies: therapeutic aspects. Ann Rheum Dis 61 Suppl 3 (2002) iii33-iii39
14. Simon A.K., Seipelt E., and Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 91 18 (1994) 8562-8566
15. Yin Z., Siegert S., Neure L., Grolms M., Liu L., Eggens U., Radbruch A., Braun J., and Sieper J. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology 38 11 (1999) 1058-1067
16. Appel H., Neure L., Kuhne M., Braun J., Rudwaleit M., and Sieper J. An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis. Clin Rheumatol 23 5 (2004) 435-440
17. Brandt J., Haibel H., Reddig J., Sieper J., and Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29 1 (2002) 118-122
18. Bober L.A., Rojas-Triana A., Jackson J.V., Leach M.W., Manfra D., Narula S.K., and Grace M.J. Regulatory effects of interleukin-4 and interleukin-10 on human neutrophil function ex vivo and on neutrophil influx in a rat model of arthritis. Arthritis Rheum 43 12 (2000) 2660-2667
19. Koch A.E., Volin M.V., Woods J.M., Kunkel S.L., Connors M.A., Harlow L.A., Woodruff D.C., Burdick M.D., and Strieter R.M. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum 44 1 (2001) 31-40
20. Ribbens C., Andre B., Kaye O., Kaiser M.J., Bonnet V., de Groote D., Franchimont N., and Malaise M.G. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur Cytokine Netw 11 4 (2000) 669-676
21. Watanabe K., Kinoshita S., and Nakagawa H. Purification and characterization of cytokine-induced neutrophil chemoattractant produced by epithelioid cell line of normal rat kidney (NRK-52E cell). Biochem Biophys Res Commun 161 3 (1989) 1093-1099
22. Takano K., and Nakagawa H. Contribution of cytokine-induced neutrophil chemoattractant CINC-2 and CINC-3 to neutrophil recruitment in lipopolysaccharide-induced inflammation in rats. Inflamm Res 50 10 (2001) 503-508
23. Bombini G., Canetti C., Rocha F.A., and Cunha F.Q. Tumour necrosis factor-alpha mediates neutrophil migration to the knee synovial cavity during immune inflammation. Eur J Pharmacol 496 1-3 (2004) 197-204
24. Leech M., Hutchinson P., Holdsworth S.R., and Morand E.F. Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis. Clin Exp Immunol 112 3 (1998) 383-388
25. Toivanen A., and Toivanen P. Reactive arthritis. Best Pract Res Clin Rheumatol 18 5 (2004) 689-703
26. Tonussi C.R., and Ferreira S.H. Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain 48 3 (1992) 421-427
27. Hermann E., Fleischer B., and Meyer zum Buschenfelde K.H. Bacteria-specific cytotoxic CD8+ T cells: a missing link in the pathogenesis of the HLA-B27-associated spondylarthropathies. Ann Med 26 5 (1994) 365-369
28. Allen R.L., Gillespie G.M., Hall F., Edmonds S., Hall M.A., Wordsworth B.P., McMichael A.J., and Bowness P. Multiple T cell expansions are found in the blood and synovial fluid of patients with reactive arthritis. J Rheumatol 24 9 (1997) 1750-1757
29. Yu D.T. Pathogenesis of reactive arthritis. Intern Med 38 2 (1999) 97-101
30. Bollow M., Fischer T., Reisshauer H., Backhaus M., Sieper J., Hamm B., and Braun J. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59 2 (2000) 135-140
31. Marker-Hermann E., and Schwab P. T-cell studies in the spondyloarthropathies. Curr Rheumatol Rep 2 4 (2000) 297-305
32. Hill Gaston J.S., and Lillicrap M.S. Arthritis associated with enteric infection. Best Pract Res Clin Rheumatol 17 2 (2003) 219-239
33. Cunha F.Q., Poole S., Lorenzetti B.B., and Ferreira S.H. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 107 3 (1992) 660-664
34. Watkins L.R., Goehler L.E., Relton J., Brewer M.T., and Maier S.F. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res 692 1-2 (1995) 244-250
35. Tonussi C.R., and Ferreira S.H. Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 82 1 (1999) 81-87
36. Williams R.O., Marinova-Mutafchieva l., Feldmann M., and Maini R.N. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol 165 12 (2000) 7240-7245
37. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89 20 (1992) 9784-9788
38. Piguet P.F., Grau G.E., Vesin C., Loetscher H., Gentz R., and Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77 4 (1992) 510-514
39. Thorbecke G.J., Shah R., Leu C.H., Kuruvilla A.P., Hardison A.M., and Palladino M.A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89 16 (1992) 7375-7379
40. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., Teoh L.A., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 1 (2003) 35-45
41. Saidenberg-kermanac'h N., Corrado A., Lemeiter D., Devernejoul M.C., Boissier M.C., and Cohen-solal M.E. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35 5 (2004) 1200-1207
42. Matsukawa A., Yoshimura T., Miyamoto K., Ohkawara S., and Yoshinaga M. Analysis of the inflammatory cytokine network among TNF alpha, IL-1 beta, IL-1 receptor antagonist, and IL-8 in LPS-induced rabbit arthritis. Lab Invest 76 5 (1997) 629-638
43. Culy C.R., and Keating G.M. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62 17 (2002) 2493-2537
44. Parada C.A., Yeh J.J., Joseph E.K., and Levine J.D. Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat. Eur J Neurosci 17 9 (2003) 1847-1852
45. Fehrenbacher J.C., Burkey T.H., Nicol G.D., and Vasko M.R. Tumor necrosis factor alpha and interleukin-1beta stimulate the expression of cyclooxygenase II but do not alter prostaglandin E(2) receptor mRNA levels in cultured dorsal root ganglia cells. Pain 113 1-2 (2005) 113-122
46. Meador R., Hsia E., Kitumnuaypong T., and Schumacher H.R. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 20 6 Suppl 28 (2002) S130-S134
47. Lerisalo-Repo M. The present knowledge of the inflammatory process and the inflammatory mediators. Pharmacol Toxicol 75 Suppl 2 (1994) 1-3
48. Watanabe K., Koizumi F., Kurashige Y., Tsurufuji S., and Nakagawa H. Rat CINC, a member of the interleukin-8 family, is a neutrophil-specific chemoattractant in vivo. Exp Mol Pathol 55 1 (1991) 30-37